Moving Beyond Spot-Treatment to All-Day ADHD Control

"Moving Beyond Spot-Treatment to All-Day ADHD Control" challenges a common assumption in ADHD care: that treatment can stop once a patient is no longer visibly struggling.

The panel discusses a philosophical shift away from what one panelist calls "spot treatment" of ADHD, where clinicians once considered a patient successfully treated as long as they were not struggling at work or school. The panel argues that any time the brain is engaged, it draws on executive function, so patients deserve coverage across every part of their day, not just the hours that are most visible to others. Dr. Parcells challenges the lingering misconception that stimulant treatment should wait until a patient is actively failing, drawing a parallel to her pediatric practice: she would never wait for an asthmatic patient to be in the ICU before starting albuterol, and the same logic should apply to ADHD.

The panel notes that succeeding at work or school can mask significant struggles elsewhere, particularly around bedtime, which Dr. Patel calls the hardest executive function task of the day because it requires setting aside a preferred activity, completing unpreferred tasks, and then lying still in a sensory-deprived environment waiting for sleep. Patients with ADHD often experience a racing "brain spin" at night that can be mistaken for anxiety, hypomania, or rumination. The panel explains that immediate-release medications tend to be more abusable, more divertable, and associated with a harder crash, which can worsen evenings and disrupt sleep. The stated goal is treating ADHD smoothly through to bedtime using longer-acting stimulants.

Up next, in "Rethinking Long-Standing ADHD Medication Regimens," the panel makes the case for revisiting medication regimens that have gone unchanged for decades.